Comparing heart effects of two hormone therapies for prostate cancer
Treatments studied
Part of Cancer, Kidney & urinary clinical trials.
This trial compares two hormone therapies, relugolix and leuprolide, to see which one is better for your heart health in men with prostate cancer. It's for men with a specific type of prostate cancer that is not yet advanced.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a diagnosis of prostate cancer (adenocarcinoma) within the last 9 months.
- Your cancer should be classified as 'unfavorable intermediate risk' (certain PSA levels, Gleason score, or stage).
- You cannot have had prior hormone therapy (like Lupron or Firmagon) for your cancer.
- You must be able to exercise (treadmill test) and have an MRI, so no claustrophobia or metal implants.
- You need to have adequate kidney, liver, and blood cell counts (tests will be done to check).
- You cannot have other serious conditions like uncontrolled heart disease, or active inflammatory diseases requiring steroids.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new hormone pill called relugolix combined with radiation therapy for men with high-risk prostate cancer. The goal is to see if this combination improves treatment outcomes.
This trial tests whether combining two hormone therapy drugs, relugolix and enzalutamide, with radiation therapy can help treat very high-risk prostate cancer. The goal is to see if this combination is safe and effective for men whose cancer has a high chance of coming back.
This trial tests whether giving a short course of hormone therapy (apalutamide) along with targeted, high-dose radiation (SBRT) is safe and effective for men with a specific type of intermediate-risk prostate cancer. You may benefit if you fit the exact risk and test criteria.
This trial tests whether some men with high-risk prostate cancer can safely receive less hormone therapy when combined with radiation. It aims to reduce side effects while still effectively treating the cancer.
This trial compares two hormone therapy combinations for men with prostate cancer that hasn't spread. The goal is to see if a newer oral medication (Relugolix) plus abiraterone works better than the standard injectable therapy (Lupron) plus abiraterone, while also checking heart safety.
This Phase 2 study compares two medicines that lower testosterone—relugolix tablets versus leuprolide injections—to see which better improves quality of life. It’s for people with prostate cancer who are starting hormone treatment and have not used similar testosterone-lowering drugs before.
Hear when a new Prostate Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.